WO2016048999A3 - Fgf21 truncations and mutants and uses thereof - Google Patents
Fgf21 truncations and mutants and uses thereof Download PDFInfo
- Publication number
- WO2016048999A3 WO2016048999A3 PCT/US2015/051406 US2015051406W WO2016048999A3 WO 2016048999 A3 WO2016048999 A3 WO 2016048999A3 US 2015051406 W US2015051406 W US 2015051406W WO 2016048999 A3 WO2016048999 A3 WO 2016048999A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- proteins
- fgf21
- mutant
- treat
- blood glucose
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title abstract 4
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title abstract 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000008300 Mutant Proteins Human genes 0.000 abstract 1
- 108010021466 Mutant Proteins Proteins 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present disclosure provides FGF21 mutant proteins, such as those having an N- terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Thus, the disclosed mutant FGF21 proteins can be used to treat one or more metabolic diseases. In some examples, mutant FGF21 proteins have reduced receptor specificity and/or reduced receptor affinity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels, for example to treat a metabolic disorder are also provided.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462053987P | 2014-09-23 | 2014-09-23 | |
| US62/053,987 | 2014-09-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2016048999A2 WO2016048999A2 (en) | 2016-03-31 |
| WO2016048999A3 true WO2016048999A3 (en) | 2016-10-27 |
Family
ID=55582240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2015/051406 WO2016048999A2 (en) | 2014-09-23 | 2015-09-22 | Fgf21 truncations and mutants and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2016048999A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6712230B2 (en) | 2014-03-11 | 2020-06-17 | ノバルティス アーゲー | Methods for treating metabolic disorders associated with lipodystrophy and defective insulin production or defective insulin signaling |
| KR20210027426A (en) | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | FGF21 formulation |
| AU2020230668A1 (en) * | 2019-03-05 | 2021-07-01 | Sunshine Lake Pharma Co., Ltd. | A polypeptide molecule and application thereof |
| WO2022194260A1 (en) * | 2021-03-19 | 2022-09-22 | Sunshine Lake Pharma Co., Ltd. | Uses of fgf21 polypeptides and fusion polypeptides thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006028714A1 (en) * | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| WO2010129600A2 (en) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| WO2012062078A1 (en) * | 2010-11-11 | 2012-05-18 | 重庆富进生物医药有限公司 | N-terminal deletion variant of human fibroblast growth factor 21 and conjugate thereof |
| WO2012066075A1 (en) * | 2010-11-19 | 2012-05-24 | Novartis Ag | Methods of treating fgf21-associated disorders |
| WO2013033452A2 (en) * | 2011-08-31 | 2013-03-07 | Amgen Inc. | Method of treating or ameliorating type 1 diabetes using fgf21 |
| WO2013131091A1 (en) * | 2012-03-02 | 2013-09-06 | New York University | Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders |
-
2015
- 2015-09-22 WO PCT/US2015/051406 patent/WO2016048999A2/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006028714A1 (en) * | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| WO2010129600A2 (en) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| WO2012062078A1 (en) * | 2010-11-11 | 2012-05-18 | 重庆富进生物医药有限公司 | N-terminal deletion variant of human fibroblast growth factor 21 and conjugate thereof |
| WO2012066075A1 (en) * | 2010-11-19 | 2012-05-24 | Novartis Ag | Methods of treating fgf21-associated disorders |
| WO2013033452A2 (en) * | 2011-08-31 | 2013-03-07 | Amgen Inc. | Method of treating or ameliorating type 1 diabetes using fgf21 |
| WO2013131091A1 (en) * | 2012-03-02 | 2013-09-06 | New York University | Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders |
Non-Patent Citations (1)
| Title |
|---|
| ADAMS, A.C. ET AL.: "LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys", PLOS ONE, vol. 8, no. 6, 2013, pages e65763, XP055268886 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016048999A2 (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016048995A3 (en) | Fgf19 truncations and mutants and uses thereof | |
| WO2016100820A3 (en) | Fgf2 truncations and mutants and uses thereof | |
| MX2016005101A (en) | Mutated fibroblast growth factor (fgf) 1 and methods of use. | |
| WO2016172156A3 (en) | Fibroblast growth factor (fgf) 1 mutants and methods of use to reduce blood glucose | |
| WO2016172153A3 (en) | Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose | |
| SA522433260B1 (en) | Rsv f protein mutants | |
| WO2018170338A3 (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| EA201491470A1 (en) | COMPOSITIONS OF FACTOR VIII AND METHODS OF OBTAINING AND USING SIMILAR | |
| MX2022003994A (en) | Production of human milk oligosaccharides in microbial hosts with engineered import / export. | |
| MX2023001394A (en) | Optimized factor viii genes. | |
| MX2018013784A (en) | Gdf15 fusion proteins and uses thereof. | |
| EP4353247A3 (en) | Fgf21 mutants and uses thereof | |
| WO2021087296A8 (en) | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems | |
| EA201690946A1 (en) | FGF21 MUTANTS AND THEIR APPLICATIONS | |
| BR112018003753A2 (en) | bifidobacterium longum | |
| MX2017014730A (en) | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3). | |
| EA201990619A1 (en) | FGF21 MUTANTS AND THEIR APPLICATION | |
| BR112015022971A2 (en) | Manufacturing methods for controlling the content of c-terminal lysine, galactose and sialic acid in recombinant proteins | |
| WO2016048999A3 (en) | Fgf21 truncations and mutants and uses thereof | |
| MX2016000393A (en) | Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase. | |
| WO2016007570A3 (en) | Engineered invariant natural killer t (inkt) cells and methods of making and using thereof | |
| BR112016023688A2 (en) | host cell, methods for producing a bioconjugate, for treating or preventing pseudomonas infection in an individual, and for inducing an immune response against pseudomonas in an individual, bioconjugate, composition, use of a bioconjugate or composition, and nucleic acid sequence isolated | |
| MX2018010196A (en) | Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof. | |
| WO2024173835A3 (en) | Methods and compositions for administering otoferlin dual vector systems | |
| BR112018076674A2 (en) | fusion protein between short-form rod derived cone viability factor and a hydrophilic peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15844479 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15844479 Country of ref document: EP Kind code of ref document: A2 |